Atropos Health
PrivateLast Round
Series B
May 23, 2024
Est. Valuation
$250M
Total Funding Raised
$47M
Company Overview
Atropos Health operates in Healthcare & Life Sciences and is based in New York City, New York. Its latest recorded funding round was a Series B round in May 2024.
Atropos Health is a healthcare technology company that provides a clinical analytics platform to convert health data into actionable real-world evidence for improved patient outcomes and medical research.
Sector
Healthcare & Life Sciences
Verticals
Healthcare Analytics, Clinical Trials, Medical AI, NLP & Conversational AI, EHR & EMR
Business Model
B2B
Customer Profile
Subscription SaaS, Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Atropos Health Comparables
Compare Atropos Health with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Medeloop | 83% | |
| Truveta | 82% | |
| nference | 82% |
For institutional investors. Book with your work email.
Atropos Health Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | May 23, 2024 | ||||
| Strategic | Sep 21, 2023 | ||||
| Series A | Aug 4, 2022 | ||||
| Seed | Dec 10, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Atropos Health Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Breyer Capital | Series B, Seed, Series A |
| StartX | Seed |
| Gaingels | Strategic, Series A |
| McKesson Ventures | Series B |
| Audere Capital | Strategic |
| McKesson Ventures | Series B |
| Valtruis | Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 21, 2026
Launched Alexandria, the world's largest medical evidence library.
- Mar 10, 2026
Michael Dnistran joins as Manager, Sales Operations.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- launchesSep 17, 2026
Atropos Health introduces Precision Evidence Bench, a Precision Medicine Benchmark that evaluates large language models on clinical questions grounded in patient context and history, in California on Sep 17th '26.
For institutional investors. Book with your work email.
Atropos Health Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Atropos Health's valuation, stock price, and market status.
Is Atropos Health a public or private company?
Atropos Health is a private company.
What is the current stock price of Atropos Health?
Atropos Health is a private company, so its shares have no public market price. Caplight tracks Atropos Health's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Atropos Health worth (valuation)?
Atropos Health's valuation is estimated at $250.0M based on funding round data.
Can I buy Atropos Health stock?
Atropos Health shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Atropos Health's last funding round?
Atropos Health's most recent funding round was Series B on May 23, 2024.
Who are the main investors in Atropos Health?
Key investors in Atropos Health include Breyer Capital, Valtruis.
Will Atropos Health IPO soon?
No public IPO plans have been announced for Atropos Health.
How can I track Atropos Health secondary market activity?
Caplight tracks bids, offers, and trades in Atropos Health's shares on secondary markets.